Robotic surgery using Senhance® robotic platform: single center experience with first 100 cases

Samalavičius, Narimantas Evaldas; Janušonis, Vinsas; Šiaulys, Raimondas; Jasėnas, Marius; Deduchovas, Olegas; Venckus, Raimondas; Ezerskiene, Viktorija; Paškevičiūtė, Renata; Klimavičiūtė, Geda

doi:10.1007/s11701-019-01000-6

Cited by 104 publications

(71 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A recent meta‐analysis suggests that open TME gives better pathological specimens but minimally invasive techniques may have advantages when considering lymph node harvest, complications and mortality . We have previously shown that the Senhance ® robotic platform is safe and feasible in all abdominal procedures including colorectal .…”

mentioning

confidence: 99%

Robotic total mesorectal excision for mid‐rectal cancer using the Senhance^® robotic platform – a video vignette

et al. 2020

View full text Add to dashboard Cite

mentioning

confidence: 99%

Robotic total mesorectal excision for mid‐rectal cancer using the Senhance^® robotic platform – a video vignette

et al. 2020

View full text Add to dashboard Cite

“…Since the initial reports of the use of the Senhance robotic platform in gynaecology 9 and colorectal surgery, 7 subsequent studies have confirmed the safety and feasibility of this system in abdominal procedures, [10][11][12][13] including colorectal surgeries. [14][15][16][17][18] In addition, previous publications have demonstrated its economic advantage over other systems for hysterectomy.…”

Section: Resultsmentioning

confidence: 96%

An early experience with the Senhance surgical robotic system in colorectal surgery: a single‐institute study

Lin

Huang

Lin

et al. 2020

Robotics Computer Surgery

View full text Add to dashboard Cite

Background We present our initial single‐centre experience with Senhance surgical robot‐assisted colorectal surgery and examine its safety and feasibility. Methods From June 2019 to December 2019, patients who underwent Senhance surgical robot‐assisted colorectal surgery in our hospital were retrospectively analysed. We focused on the short‐term outcomes. Results In total, 46 patients were enrolled in the study. Colorectal cancer was the most common indication for surgery (39 patients). The median total operation time was 283 min, and the median blood loss was 50 cc. Meanwhile, the median number of harvested lymph nodes was 20. Elderly age, advanced American Society of Anaesthesiologists stage, and right‐sided colon surgery were associated with the occurrence of complications greater than grade III. Conclusion Our findings demonstrate the feasibility and safety of the Senhance surgical robotic system in colorectal surgery. Care should be taken regarding the indications and patient selection.

show abstract

“…The high cost of robotic surgery is also a problem, which make it cannot be widely recommended for patients. Nevertheless, the robotic system is continuously being improved and more advanced technologies will be developed, such as a novel Senhance® robotic system (TransEnterix Surgical Inc., Morrisville, NC, USA), which has been proved to be feasible and safe in general surgery, gynecology, and urology [23]. We suppose the cost of robotic system will become more and more acceptable…”

Section: Discussionmentioning

confidence: 99%

No beneficial effect on survival but with a decreased postoperative adverse events for robotic surgery in patients with rectal cancer: A retrospective cohort study

Xiong

Yang

Huang

et al. 2021

Preprint

View full text Add to dashboard Cite

Aim To compare the oncologic outcomes in patients with rectal cancer receiving robotic vs. laparoscopic surgery. Methods The clinical data of patients with rectal cancer receiving robotic surgery (Robot group, n = 317) or laparoscopic surgery (Laparoscopy group, n = 224) were collected for outcomes assessment. The primary endpoints were the survival outcome. The secondary outcomes were postoperative adverse events and pathologic characteristics. Results Patients in the Robot group have significantly shorter operation time (163.6 ± 41.1vs.190.6 ± 52.5min), shorter time to 1st gas passing [2(1)vs.3(1)d] and shorter hospital day [7(2)vs.8(3)d], compared to those in Laparoscopy group (P < 0.001, respectively). The incidence of urinary retention short- and long term in Robot group is significant lower than in Laparoscopy group (1.9% vs. 10.7%; 0.6% vs. 4.0%, P < 0.05, respectively). TNM stage II and III was more frequently observed in the Robot group than that in the Laparoscopy group (94.3% vs. 83.5%), whereas stage I was more common in the Laparoscopy group than in the Robot group (5.7% vs. 16.5%). No significant difference in the overall survival (OS) and disease-free survival (DFS) were observed in Robot group and Laparoscopy group at 1-, 3- and 5-year. By a multivariable-adjusted analysis, the robotic surgery was not an independent prognostic factor for OS and DFS. Conclusions A beneficial effect on survival of the robotic surgery for rectal cancer could not be demonstrated. However, the robot is a feasible surgical procedure due to the decreased postoperative adverse event.

show abstract

Robotic surgery using Senhance® robotic platform: single center experience with first 100 cases

Cited by 104 publications

References 25 publications

Robotic total mesorectal excision for mid‐rectal cancer using the Senhance^® robotic platform – a video vignette

Robotic total mesorectal excision for mid‐rectal cancer using the Senhance^® robotic platform – a video vignette

An early experience with the Senhance surgical robotic system in colorectal surgery: a single‐institute study

No beneficial effect on survival but with a decreased postoperative adverse events for robotic surgery in patients with rectal cancer: A retrospective cohort study

Contact Info

Product

Resources

About

Robotic surgery using Senhance® robotic platform: single center experience with first 100 cases

Cited by 104 publications

References 25 publications

Robotic total mesorectal excision for mid‐rectal cancer using the Senhance® robotic platform – a video vignette

Robotic total mesorectal excision for mid‐rectal cancer using the Senhance® robotic platform – a video vignette

An early experience with the Senhance surgical robotic system in colorectal surgery: a single‐institute study

No beneficial effect on survival but with a decreased postoperative adverse events for robotic surgery in patients with rectal cancer: A retrospective cohort study

Contact Info

Product

Resources

About

Robotic total mesorectal excision for mid‐rectal cancer using the Senhance^® robotic platform – a video vignette

Robotic total mesorectal excision for mid‐rectal cancer using the Senhance^® robotic platform – a video vignette